122 results about "Dyskinesia" patented technology

The invention discloses a Parkinson's dyskinesia individualized SCAN network positioning method based on a multi-modal image and deep learning. The method comprises the steps of obtaining multi-modal medical image data, preprocessing the multi-modal medical image data, obtaining a multi-modal structure image and functional connection data, and calculating a spontaneous neural activity index of a whole-brain voxel level; taking a priori brain region related to the spontaneous neural activity index and dyskinesia as a seed point, constructing a seed point voxel function connection graph representing individual brain function connection, and performing nonlinear feature fusion and extraction through the deep learning network model; the bilinear attention network is adopted to capture the interaction information of the feature data and the individual dyskinesia symptom which is significantly related, an individualized SCAN network positioning result is obtained, the structure-function coupling characteristics of the individual brain are comprehensively described, the cross-modal pathological features related to the dyskinesia can be more sensitively recognized, and the accuracy and accuracy of the diagnosis and treatment of the dyskinesia can be improved. And the accuracy and robustness of abnormal brain region detection are obviously improved.

The invention relates to the technical field of data processing, and discloses a gait rehabilitation evaluation method and system based on spatial-temporal characteristics of multi-modal data, a terminal and a storage medium, and the method comprises the steps: synchronously collecting myoelectricity, electroencephalogram and exoskeleton robot IMU signals of a dyskinesia crowd in a certain motion normal form in a specific period interval; a motion function scoring result of a doctor on a patient according to a scale is synchronously recorded, data preprocessing, channel selection and feature extraction are performed on myoelectricity, electroencephalogram and exoskeleton robot IMU signals, a model is established based on a neural network, motion evaluation is performed according to a fused feature array, and a motion function quantitative score is obtained; and the motion function state of the evaluated person is graded according to the score. According to the method, the multi-modal synchronous data rehabilitation evaluation model of the movement function of the dyskinesia crowd is constructed according to multiple information mining, and the movement function state of the evaluated person is rapidly evaluated, predicted and graded.

The invention discloses a gait intervention method, a music generation method, a device, a system, equipment and a medium for people suffering from dyskinesia diseases, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: in the process of performing abnormal gait intervention treatment on a target object suffering from dyskinesia according to rhythmic music, acquiring multi-modal physiological data of the target object in real time, and dynamically determining a plurality of gait-related movement symptom characteristic indexes of the target object according to the multi-modal physiological data; determining music parameters at each moment in real time according to the multiple exercise symptom characteristic indexes; and dynamically adjusting notes of the rhythmic music at each moment according to the music parameters at each moment, and generating the rhythmic music adaptive to the current gait condition of the target object. According to the scheme, the rhythm music can be dynamically adjusted more comprehensively and individually, the current gait condition of the target object can be better met and adapted, and the effect of abnormal gait rehabilitation treatment, intervention and correction can be improved.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The invention provides a rehabilitation training plan processing method, a brain-computer interface device and a storage medium, and relates to the technical field of brain-computer interfaces. According to the method, the motor imagery ability evaluation result of the target object is obtained mainly based on the electroencephalogram signal of the target object, that is, the motor imagery ability of different patients can be quantitatively evaluated according to the scheme; then, aiming at the two indexes of the motor imagery ability evaluation result and the dyskinesia level of the patient, a rehabilitation training plan is generated for the patient in a personalized manner, namely, the rehabilitation plan has the characteristics of pertinence, scientificity, reasonability and the like, so that the rehabilitation efficiency of the patient is greatly improved, and the rehabilitation time of the patient is saved; meanwhile, the use efficiency of the rehabilitation robot is improved, that is, the rehabilitation effect of the motor imagery therapy is better than that of a traditional rehabilitation method, and the problem that in the prior art, rehabilitation training is unreasonable in formulation is solved.

The present invention provides a method and system for classifying infant behavior characteristics based on deep learning, including: Step 1: Produce an infant video dataset, and classify and annotate time segments for the videos in the dataset; Step 2: Produce an infant key point dataset; Step 3: Preprocess the human key points of the infant video dataset; Step 4: Use a deep learning model to build an infant behavior classification model, send the human key point features of the infant video dataset into the infant behavior classification model, calculate the classification probability output by the model, the total loss between the output time segment and the label, and use the total loss for backpropagation to update the model parameters. After the model parameters converge, the training is completed; Step 5: Judge whether there is a dyskinesia in the video according to the classification probability of the classification branch, and obtain the time segment when there is a dyskinesia in the video. The present invention can detect whether an infant lacks dyskinesia and relieve the burden on doctors of having to watch infant movement videos for a long time.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.

The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and / or mobility and / or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The invention discloses a daily life activity ability assessment method and system based on a multi-branch space-time fusion network. The method comprises the steps of collecting motion data of a to-be-evaluated object, performing segmentation, noise reduction and standardization preprocessing, and extracting time-frequency domain features and motion deviation degree, motion similarity index and bilateral symmetry index provided by the invention; obtaining a uniform Bhattacharyya index scale score; and taking the motion feature data set and the clinical score as input, performing training based on a multi-branch space-time fusion algorithm, constructing a multi-task prediction model, and realizing automatic evaluation of the ADL. According to the method, the multi-branch space-time fusion network is innovatively introduced, the relevance between tasks is fully utilized, the spatial feature extraction capability is enhanced in combination with the graph neural network, adaptive fusion of the features is realized through a cross-layer interactive attention mechanism, the model prediction precision and evaluation reliability are remarkably improved, and the method is suitable for large-scale popularization and application. And an effective technical support is provided for rehabilitation evaluation and personalized treatment of patients with dyskinesia and disability and dementia.

The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternatively, a synthetically produced THCV is used.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating Parkinson's disease, namely tremor syndrome of traditional Chinese medicine, which comprises the following raw materials by weight: 390-470g of liver calming and wind calming medicine, 140-160g of radix rehmanniae, 280-320g of radix paeoniae alba, 840-960g of first decoction medicine, 390-450g of blood activating and qi regulating and tendon and collateral dredging medicine, and 305-355g of antidote. The traditional Chinese medicine composition has remarkable effects of relaxing tendons and detoxifying, and calming endogenous wind and arresting fibrillation, can play a role in solving the problems of head shaking, limb tremor, muscle stiffness, dyskinesia and the like caused by liver wind internal movement and kidney deficiency and toxic damage of Parkinson's disease, and can nourish liver and kidney, relieve tendon and vessel contracture and relieve pain due to the synergistic effect of various traditional Chinese medicinal materials contained in the traditional Chinese medicine composition. The traditional Chinese medicine composition is especially suitable for Parkinson patients with liver-wind internal movement and kidney deficiency and toxicity loss, and can gradually improve the neurotransmitter level in the brain after being taken. The traditional Chinese medicine composition has an outstanding detoxification effect, can effectively remove accumulation of pathological products such as phlegm and blood stasis in the body of the Parkinson's disease patient, prevents phlegm and blood stasis from generating toxins, and can relieve medicine poison generated by long-term medicine taking of the patient.

This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.

The invention discloses a flexible shoulder rehabilitation exoskeleton based on a pneumatic folding driver, and the flexible shoulder rehabilitation exoskeleton comprises a trunk module, a shoulder module, a connecting assembly, a flexible folding pneumatic driving module, a multi-mode sensing module and a control terminal. By introducing the design of alternating internal folding and external folding, geometric dislocation between the driver and the joint axis is effectively compensated, and continuous high output torque is provided. The control system recognizes the motion intention of a user by collecting surface electromyogram signals and inertia measurement data through threshold judgment logic, and adjusts an electromagnetic proportional valve through a PID algorithm in combination with feedback of an air pressure sensor to achieve closed-loop accurate control over air pressure. The device has the advantages of light weight, high wearing comfort and excellent mechanical transparency, muscle load in rehabilitation training can be remarkably reduced, and the device is suitable for daily assistance and rehabilitation training of patients suffering from upper limb dyskinesia.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.

The invention belongs to the technical field of animal models, and particularly discloses a method for constructing a primary ciliary dyskinesia hydrocephalus model, which comprises the following steps: screening benzimidazole as a molding agent; performing benzimidazole solution administration on the experimental animals, and setting a blank control group; carrying out experimental verification through pathological morphology and behavioral methods; the ventricle of the experimental animal is obviously enlarged, the athletic ability is obviously reduced, and if the condition is met, the primary ciliary dyskinesia hydrocephalus model is successfully constructed. According to the new method for constructing the primary ciliary dyskinesia hydrocephalus model, the constructed hydrocephalus model is good in stability and repeatability, objective, simple and high in operability, and other possible interference factors are reduced; and a necessary experimental basis is provided for research on the mechanism of hydrocephalus caused by primary ciliary dyskinesia and development of treatment means.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The present invention relates to food and pharmaceutical compositions for inhibiting tremor or dyskinesia comprising a novel aldehyde dehydrogenase encoded by a gene having more than 98% homology with the gene of SEQ ID NO: 1. Furthermore, the present invention relates to a food composition and a pharmaceutical composition for inhibiting tremor or dyskinesia, said composition comprising a lysate of any one selected from the group consisting of KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14983BP, KCTC 14984BP and KCTC 14985BP, or a mixture thereof.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present disclosure relates to compositions and methods for the treatment of dyskinesia using a pharmaceutical composition comprising 3-methylmethcathinone (3MMC), or a pharmaceutically acceptable salt thereof.

The invention relates to application research of Dunaliella sp. Or metabolites thereof in preparation of drugs for prevention or treatment of Parkinson's disease, Dunaliella sp. Can produce L-DOPA and analogues thereof through metabolism, and the Dunaliella sp. Is a promising drug for treatment of Parkinson's disease. In addition, the main metabolite indoleacetic acid (IAA) of the dunaliella can significantly improve the dyskinesia of PD mice, relieve the loss of dopaminergic neurons in the brain and reduce neuroinflammation, thereby delaying the PD process. The intestinal symbiotic bacterium Dunaliella sp. And the metabolite thereof provided by the invention have a good effect of treating or preventing Parkinson's disease, and the Dunaliella sp. Metabolites to generate L-DOPA and analogues thereof, so that the Dunaliella sp. Is a potential PD treatment medicine and is suitable for clinical popularization.

The invention discloses a pharmaceutical composition for preventing and / or treating Parkinson's disease and application of the pharmaceutical composition, and relates to the technical field of biological medicine. The composition comprises nervonic acid, salvianolic acid A and pharmaceutically acceptable auxiliary materials. Experiments prove that the composition can improve intestinal flora, obviously promote alleviation of symptoms of a Parkinson's disease model animal, promote regeneration of dopaminergic neuronal cells and neural stem cells, relieve neuroinflammation, promote repair of damaged nerves, improve dyskinesia of mice caused by Parkinson's disease and improve the Parkinson's disease resistance of the mice. Therefore, the polypeptide has potential application value in treatment of the human Parkinson's disease. According to the invention, the effect of the composition is confirmed from the perspective of improving the change of intestinal flora by utilizing the relationship of the brain-intestinal axis, and a basis is provided for intervening the treatment of Parkinson's disease through the intestinal flora.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The invention discloses a multi-degree-of-freedom bionic foot rehabilitation robot device which comprises an outer frame, a four-section bionic foot bottom plate and a parallel driving mechanism. The four-section type bionic foot bottom plate is connected through a rotating shaft hinge and a sliding block and sliding rod structure, and biomechanical movement of a foot posterior area, a foot middle area, a foot anterior area and a phalanx area of a human foot is simulated. And the parallel driving mechanism realizes multi-degree-of-freedom movement and deformation compensation of the ankle joint and the foot by adjusting the posture of each foot bottom plate section. The device can be worn on the foot and is suitable for rehabilitation training of patients with lower limb dyskinesia.